To date, a series of CAR-T therapeutic targets have been identified toward GBM, including epidermal growth factor receptor variant III, interleukin-13 receptor subunit alpha-2, HER2, B7 homolog 3 protein, CD70, disialoganglioside, matrix metalloproteinase-2, and natural killer group 2, member D [14]. This evidence concerns the gene ERBB2 and glioblastoma.